The Johnson & Johnson (NYSE: JNJ) unit Janssen appears to have one of the hottest prospects in neuroscience on its hands in the shape of esketamine, but that it not to say it is proving immune to encountering the challenges of this tricky therapy area.
While a nasal spray formulation of the drug showed impressive efficacy results in two long-term Phase III clinical studies in treatment-resistant depression (TRD), there were some notable issues on the safety side.
These studies, one that showed a delayed time to relapse and a second that provided evidence of safe long-term use of esketamine, were presented at the Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP) in Florida on Thursday.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze